Geron Corp., of Menlo Park, Calif., appointed Alan Colowick as president of oncology.
Human Genome Sciences Inc., of Rockville, Md., appointed Kevin Starr to its board.
ImClone Systems Inc., of New York, appointed Peter Liebert to its board.
Indevus Pharmaceuticals Inc., of Lexington, Mass., appointed Thomas Forest Farb as president and chief operating officer.
Infinity Pharmaceuticals Inc., of Cambridge, Mass., appointed Gerald Quirk as vice president and general counsel, Steven Kafka as vice president of strategic product planning and finance, and John Evans as manager of investor relations and business development.
InterMune Inc., of Brisbane, Calif., elected Lars Ekman to its board.
KaloBios Pharmaceuticals Inc., of Palo Alto, Calif., appointed David Pritchard as president and CEO.
Kalypsys Inc., of San Diego, appointed Richard Heyman as senior vice president of drug discovery, and Richard Lai Fatt as vice president of corporate development.
Keryx Biopharmaceuticals Inc., of New York, appointed Jack Kaye to its board.
Ligand Pharmaceuticals Inc., of San Diego, elected Jason Aryeh to its board.
Lorus Therapeutics Inc., of Toronto, named Aiping Young as president and CEO, and appointed Georg Ludwig and Michael Moore to its board.
Lpath Inc., of San Diego, appointed Genevieve Hansen as vice president of research.
MacroGenics Inc., of Rockville, Md., appointed John Maraganore to its board.
MAP Pharmaceuticals Inc., of Mountain View, Calif., appointed Christopher Chai as chief financial officer.
MerLion Pharmaceuticals Pte. Ltd., of Singapore, appointed Klaus Brandau, Clemens Doppler and Harald Labischinski to its board.
Neurocrine Biosciences Inc., of San Diego, appointed Kevin Gorman as chief operating officer.
NovaDel Pharma Inc., of Flemington, N.J., appointed Steven Ratoff as chairman.
Novavax Inc., of Malvern, Pa., appointed Penny Heaton as chief medical officer.
Oridis Biomed, of Graz, Austria, appointed Wolfgang Senne as chief financial officer.
Panacea Pharmaceuticals Inc., of Gaithersburg, Md., appointed Christine Brauer as vice president of regulatory affairs and Jefferey Jones as director of quality.
Penwest Pharmaceuticals Co., of Danbury, Conn., appointed Amy O'Donnell as senior director of clinical development.
PharmaVentures, of Oxford, UK, named Charles Macfarlane to its board.
Pharmos Corp., of Iselin, N.J., appointed S. Colin Neill as senior vice president, chief financial officer, secretary and treasurer.
Plexxikon Inc., of Berkeley, Calif., appointed Fletcher Payne as vice president and chief financial officer.
ProEthic Pharmaceuticals Inc., of Montgomery, Ala., appointed Roger Graben as vice president of business development.